Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) announced the pricing of its previously announced underwritten public offering of $400 million aggregate principal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE